Vietnam's pharmaceutical drug delivery market is experiencing sustained growth as the country expands access to advanced medicines, strengthens domestic pharmaceutical manufacturing and invests in next-generation healthcare technologies.
According to IMARC Group, Vietnam's pharmaceutical drug delivery market reached US$7.7 billion in 2025 and is projected to grow to US$12.2 billion by 2034. The market is being driven by an ageing population, increasing prevalence of chronic diseases and rising demand for more effective and patient-friendly drug delivery systems.
The sector forms a critical part of Vietnam's rapidly expanding pharmaceutical industry. IMARC estimates the country's overall pharmaceutical market was valued at US$8.0 billion in 2025 and is expected to reach US$14.6 billion by 2034. Rising healthcare expenditure, expanding insurance coverage and increasing investment in healthcare infrastructure are supporting demand for innovative medicines and delivery technologies.
Several long-term trends are accelerating growth across the pharmaceutical drug delivery market:
- Rising incidence of cancer, diabetes, cardiovascular disease and other chronic conditions requiring long-term treatment.
- Growing adoption of biologics, specialty medicines and personalised therapies.
- Expansion of domestic pharmaceutical manufacturing and contract manufacturing capabilities.
- Increasing demand for self-administered medicines and home healthcare solutions.
- Advances in sustained-release, controlled-release and targeted drug delivery technologies.
- Greater investment in injectable therapies, prefilled syringes, autoinjectors and wearable drug delivery devices.
Drug delivery technologies are becoming increasingly sophisticated, enabling medicines to be delivered more precisely, safely and effectively. Innovations including nanotechnology-based delivery systems, implantable devices, inhalation therapies and transdermal platforms are improving treatment outcomes while enhancing patient adherence and reducing side effects. These technologies are particularly important for high-growth therapeutic areas such as oncology, diabetes, autoimmune diseases and rare diseases.
The market also reflects broader regional momentum. Across Southeast Asia, the pharmaceutical drug delivery market reached US$30.1 billion in 2025 and is forecast to expand to US$57.4 billion by 2034, driven by increasing demand for personalised therapies and continued pharmaceutical innovation.
Global pharmaceutical companies including Pfizer, Roche, Novartis, Sanofi, AstraZeneca, Novo Nordisk and Johnson & Johnson, alongside specialist delivery technology providers such as West Pharmaceutical Services, Gerresheimer, SCHOTT Pharma, Catalent and Becton Dickinson (BD), continue to invest in advanced delivery platforms that improve therapeutic performance and patient experience.
As Vietnam continues to modernise its healthcare system and strengthen its pharmaceutical manufacturing base, advanced drug delivery technologies are expected to play an increasingly important role in supporting precision medicine, biologics and next-generation therapeutics. For suppliers of drug delivery devices, packaging solutions, injectable technologies and pharmaceutical manufacturing equipment, Vietnam represents one of Southeast Asia's most attractive long-term growth markets.
